0000000000156903

AUTHOR

Letizia Mattii

0000-0001-6835-7987

showing 2 related works from this author

Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy

2021

Background: Ponatinib (PON), a third-generation tyrosine kinase inhibitor (TKI), has proven cardiovascular toxicity, with no known preventing agents usable to limit such side effect. Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are a new class of glucose-lowering agents, featuring favorable cardiac and vascular effects. Aims: We assessed the effects of the SGLT2 inhibitors empagliflozin (EMPA) and dapagliflozin (DAPA) on human aortic endothelial cells (HAECs) and underlying vasculo-protective mechanisms in an in vitro model of PON-induced endothelial toxicity. Methods and results: We exposed HAECs to PON or vehicle (DMSO) in the presence or absence of EMPA (100 and 500 nmol/L) or …

Physiologymedicine.drug_classCellPharmacologyAutophagy; Ponatinib; Sodium-glucose cotransporter type 2 (SGLT2) inhibitors; Tyrosine kinase inhibitors; Vascular toxicityTyrosine-kinase inhibitorFlow cytometrychemistry.chemical_compoundmedicineAutophagyHumansViability assayDapagliflozinCellular SenescencePharmacologyTyrosine kinase inhibitorsMatrigelmedicine.diagnostic_testChemistrySodiumImidazolesEndothelial CellsEndothelial stem cellPyridazinesmedicine.anatomical_structureGlucoseDiabetes Mellitus Type 2Sodium-glucose cotransporter type 2 (SGLT2) inhibitorsToxicityPonatinibMolecular MedicineVascular toxicity
researchProduct

High concentration of C-type natriuretic peptide promotes VEGF-dependent vasculogenesis in the remodeled region of infarcted swine heart with preserv…

2013

Vasculogenesis is a hallmark of myocardial restoration. Post-ischemic late remodeling is associated with pathology and function worsening. At the same time, neo-vasculogenesis helps function improving and requires the release of vascular endothelial growth factor type A (VEGF-A). The vasculogenic role of C-type natriuretic peptide (CNP), a cardiac paracrine hormone, is unknown in infarcted hearts with preserved left ventricular (LV) ejection fraction (EF). We explored whether myocardial VEGF-dependent vasculogenesis is affected by CNP.To this end, infarcted swine hearts were investigated by magnetic resonance imaging (MRI), histological and molecular assays. At the fourth week, MRI showed t…

MaleVascular Endothelial Growth Factor AC-type natriuretic peptide Ischemic remodeling Myocardial infarction Paracrinicity Vasculogenesis VEGFmedicine.medical_specialtymedicine.drug_classSwineMyocardial InfarctionNeovascularization PhysiologicVentricular Function Leftchemistry.chemical_compoundVasculogenesisParacrinicityInternal medicineVasculogenesismedicineNatriuretic peptideAnimalsMyocardial infarctionVentricular remodelingEjection fractionmedicine.diagnostic_testVentricular Remodelingbusiness.industryMagnetic resonance imagingNatriuretic Peptide C-Typemedicine.diseaseVEGFVascular endothelial growth factorVascular endothelial growth factor AchemistryIschemic remodelingCardiologyCardiology and Cardiovascular MedicinebusinessC-type natriuretic peptideInternational journal of cardiology
researchProduct